Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cardiff Oncology (CRDF), a clinical-stage biotech company focused on PLK1 inhibition for cancer therapies, has granted stock options as an employment inducement. The company issued non-qualified stock options for 35,040 shares to one new employee on April 14, 2025.
The options were granted under Nasdaq Listing Rule 5635(c)(4) with an exercise price of $2.79 per share, matching Cardiff's closing stock price on April 14, 2025. The vesting schedule spans 4 years, with 25% vesting after the first year and the remainder vesting monthly over the following 36 months, contingent on continued employment.
Cardiff Oncology (CRDF), un'azienda biotech in fase clinica focalizzata sull'inibizione di PLK1 per terapie oncologiche, ha concesso opzioni su azioni come incentivo all'assunzione. Il 14 aprile 2025, la società ha emesso opzioni su azioni non qualificate per 35.040 azioni a un nuovo dipendente.
Le opzioni sono state concesse secondo la Regola Nasdaq 5635(c)(4) con un prezzo di esercizio di 2,79 $ per azione, corrispondente al prezzo di chiusura delle azioni di Cardiff del 14 aprile 2025. Il piano di maturazione si estende su 4 anni, con il 25% delle azioni maturate dopo il primo anno e il restante 75% che matura mensilmente nei successivi 36 mesi, subordinato alla continuazione del rapporto di lavoro.
Cardiff Oncology (CRDF), una empresa biotecnológica en etapa clínica enfocada en la inhibición de PLK1 para terapias contra el cáncer, ha otorgado opciones sobre acciones como incentivo laboral. El 14 de abril de 2025, la compañía emitió opciones sobre acciones no calificadas por 35,040 acciones a un nuevo empleado.
Las opciones se concedieron bajo la Regla Nasdaq 5635(c)(4) con un precio de ejercicio de $2.79 por acción, igualando el precio de cierre de las acciones de Cardiff el 14 de abril de 2025. El calendario de adquisición de derechos abarca 4 años, con un 25% adquirido tras el primer año y el resto adquirido mensualmente durante los siguientes 36 meses, condicionado a la continuidad laboral.
Cardiff Oncology (CRDF)는 암 치료를 위한 PLK1 억제에 중점을 둔 임상 단계 바이오텍 회사로, 고용 유인을 위해 스톡 옵션을 부여했습니다. 2025년 4월 14일, 회사는 신규 직원 한 명에게 35,040주의 비자격 스톡 옵션을 발행했습니다.
옵션은 나스닥 상장 규칙 5635(c)(4)에 따라 부여되었으며, 행사 가격은 2025년 4월 14일 Cardiff 종가와 동일한 $2.79입니다. 권리 확정 일정은 4년에 걸쳐 진행되며, 첫 해 후 25%가 확정되고, 나머지 75%는 이후 36개월 동안 매월 확정되며, 계속 고용 조건이 붙습니다.
Cardiff Oncology (CRDF), une société biotechnologique en phase clinique spécialisée dans l'inhibition de PLK1 pour les thérapies contre le cancer, a accordé des options d'achat d'actions en tant qu'incitation à l'embauche. Le 14 avril 2025, la société a émis des options d'achat d'actions non qualifiées pour 35 040 actions à un nouvel employé.
Les options ont été accordées conformément à la règle Nasdaq 5635(c)(4) avec un prix d'exercice de 2,79 $ par action, correspondant au cours de clôture de Cardiff le 14 avril 2025. Le calendrier d'acquisition s'étend sur 4 ans, avec 25 % acquis après la première année et le reste acquis mensuellement au cours des 36 mois suivants, sous condition de maintien en emploi.
Cardiff Oncology (CRDF), ein klinisch orientiertes Biotechnologieunternehmen mit Fokus auf PLK1-Hemmung für Krebstherapien, hat Aktienoptionen als Anreiz zur Einstellung gewährt. Am 14. April 2025 gab das Unternehmen nicht qualifizierte Aktienoptionen für 35.040 Aktien an einen neuen Mitarbeiter aus.
Die Optionen wurden gemäß Nasdaq-Listenregel 5635(c)(4) mit einem Ausübungspreis von 2,79 $ pro Aktie gewährt, was dem Schlusskurs von Cardiff am 14. April 2025 entspricht. Der Vesting-Zeitplan erstreckt sich über 4 Jahre, wobei 25 % nach dem ersten Jahr und der Rest monatlich über die folgenden 36 Monate vestet, abhängig von der fortgesetzten Beschäftigung.
- None.
- None.
SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that on April 14, 2025, non-qualified stock option awards to purchase an aggregate of 35,040 shares of its common stock were granted to one new employee. The stock options were granted as inducements material to the new employee becoming an employee of Cardiff Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
kiki@gilmartinir.com
Media Contact:
Michael Laurer
Taft Communications
732-233-4881
michael.lauer@rfbinder.com
FAQ
What stock options did Cardiff Oncology (CRDF) grant on April 14, 2025?
What is the vesting schedule for CRDF's April 2025 stock options grant?
Under which Nasdaq rule did Cardiff Oncology issue the April 2025 stock options?
What was Cardiff Oncology's (CRDF) stock price on April 14, 2025?
